Zeo ScientifiX raises $2.05M to push stem cell therapies into new state markets
What's the deal? Zeo ScientifiXDealroom has a profile for this one. Try Dealroom →, the regenerative medicine company formerly known as Organicell, raised $2.05 million in a private placement, according to its transition 10-K filed with the Securities and Exchange Commission on October 13, 2026. Between November 2025 and June 2026, it sold 8.2 units to 15 investors, issuing 512,500 shares and 512,500 warrants exercisable at $4.00 until November 2030.
Why now? The raise coincides with a wave of state laws opening the market for its products. Florida's SB 1768, effective July 1, 2025, lets licensed physicians administer certain non-FDA-approved stem cell therapies for orthopedic conditions, wound care, and pain management. Tennessee and Georgia passed similar laws effective July 1, 2026, with Texas, Mississippi, North Carolina, Nevada, and Utah adopting related measures.
What's the endgame? Zeo wants to commercialise regenerative medicine under those state frameworks while pursuing FDA Phase 2b trials. In January, it announced a partnership with Israel-based Cytora TherapeuticsDealroom has a profile for this one. Try Dealroom → and US cell therapy manufacturer Made ScientificDealroom has a profile for this one. Try Dealroom → to advance an off-the-shelf oral mucosal stem cell therapy — Cytora supplying manufacturing rights, Made Scientific as exclusive US manufacturer, and Zeo as exclusive US commercial partner.
The company believes the laws could broaden physician and patient access, lift demand, and cut the cost and risk of FDA submissions by enabling real-world data collection.
Deal activity: The filing also detailed recent restructuring. Zeo sold its membership interests in Exotropin, LLCDealroom has a profile for this one. Try Dealroom → in a deal that closed April 7, 2026, resolving a pending lawsuit that Exotropin dismissed with prejudice. In May, Zeo formed Serephon LLCDealroom has a profile for this one. Try Dealroom → with its chief executive officer, chief medical officer, and Greyt VenturesDealroom has a profile for this one. Try Dealroom → to act as a management services organisation for physician-owned practices, taking an initial 50% stake.
What could go wrong? Zeo said it does not have enough working capital to fund the substantial costs of completing its clinical trials and needs more capital for operations and expansion. It also noted that complying with state law does not guarantee federal approval.
The signal: The round is small, but it marks how regenerative medicine firms are using a patchwork of state laws to reach patients ahead of full FDA clearance — building revenue and real-world data while the longer regulatory path plays out.
Read more: minichart.com.sg
Image credit: NIH-NCATS
